🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "huge turning point" in the fight against superbug strains of the infection, according to health experts.

An International Health Concern

The sexually transmitted infection are on the rise around the world, with figures suggesting in excess of 82 million infections annually. Notably increased rates are reported in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the reality of growing infection rates, escalating drug resistance and the very limited available drugs at this time.”

Health officials are deeply concerned about the rise in drug-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program found that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Receive Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This STI can lead to major issues, including infertility. Scientists hope that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is also used to treat UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This authorization marks a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Outcomes and Global Access

As per data released by a major medical journal, the new drug successfully treated over nine in ten of cases of the STI. This puts it on an similar efficacy with the typical regimen, which involves an injection and a pill. The research included nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to register and commercialise the drug in numerous developing nations.

Clinicians treating patients have expressed positive views. Having a one-pill regimen like this is hailed as a "game-changer" for managing the epidemic. This is deemed essential to alleviate the strain of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.